Journey Strategic Wealth LLC Buys Shares of 8,486 Sanofi $SNY

Journey Strategic Wealth LLC bought a new stake in shares of Sanofi (NASDAQ:SNY) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 8,486 shares of the company’s stock, valued at approximately $410,000.

Several other hedge funds have also made changes to their positions in SNY. Voya Investment Management LLC increased its position in Sanofi by 11.6% in the first quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock worth $11,460,000 after buying an additional 21,540 shares during the period. Ascent Group LLC acquired a new position in shares of Sanofi during the first quarter valued at $426,000. 1248 Management LLC bought a new position in shares of Sanofi during the first quarter worth about $518,000. Equity Investment Corp increased its holdings in shares of Sanofi by 2.5% in the 2nd quarter. Equity Investment Corp now owns 2,512,435 shares of the company’s stock worth $121,376,000 after acquiring an additional 62,109 shares during the period. Finally, Simon Quick Advisors LLC bought a new stake in Sanofi in the 2nd quarter valued at about $246,000. Institutional investors own 14.03% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $49.63 on Friday. The stock has a market cap of $121.87 billion, a price-to-earnings ratio of 11.62, a PEG ratio of 1.38 and a beta of 0.49. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The stock’s 50 day moving average price is $49.29 and its 200 day moving average price is $49.29.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company had revenue of $14.53 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same period last year, the firm earned $2.25 EPS. The firm’s revenue for the quarter was down 7.5% on a year-over-year basis. Equities research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on SNY shares. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research report on Tuesday, November 11th. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Sanofi has a consensus rating of “Buy” and an average price target of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.